Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v2.4.1.9
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 3,970us-gaap_CashAndCashEquivalentsAtCarryingValue $ 1,034us-gaap_CashAndCashEquivalentsAtCarryingValue
Accounts receivable 122us-gaap_AccountsReceivableNetCurrent   
Marketable securities 1,975us-gaap_MarketableSecurities   
Prepaid and other current assets 144us-gaap_PrepaidExpenseAndOtherAssetsCurrent 139us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Mortgage note receivable, current portion 165cocp_MortgageNoteReceivableCurrentPortion   
Total current assets 6,376us-gaap_AssetsCurrent 1,173us-gaap_AssetsCurrent
Property and equipment, net 284us-gaap_PropertyPlantAndEquipmentNet 469us-gaap_PropertyPlantAndEquipmentNet
Deposits 31us-gaap_DepositsAssets 19us-gaap_DepositsAssets
Mortgage note receivable, long-term portion 2,431cocp_MortgageNoteReceivableLongtermPortion   
In process research and development 184,966us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment   
Goodwill 65,195us-gaap_Goodwill   
Total Assets 259,283us-gaap_Assets 1,661us-gaap_Assets
Current liabilities:    
Accounts payable 299us-gaap_AccountsPayableCurrent 224us-gaap_AccountsPayableCurrent
Accrued expenses 394us-gaap_AccruedLiabilitiesCurrent 139us-gaap_AccruedLiabilitiesCurrent
Derivative liabilities 8,464us-gaap_DerivativeLiabilities 23us-gaap_DerivativeLiabilities
Total current liabilities 9,157us-gaap_LiabilitiesCurrent 386us-gaap_LiabilitiesCurrent
Deferred rent 62us-gaap_DeferredRentCredit   
Deferred tax liability 65,195us-gaap_DeferredTaxLiabilitiesNoncurrent   
Total long-term liabilities 65,257us-gaap_LongTermDebt   
Total liabilities 74,414us-gaap_Liabilities 386us-gaap_Liabilities
Commitments and contingencies      
Cocrystal Discovery, Inc. Series A convertible preferred stock, $0.001 par value; 7,150 shares authorized; 0 and 7,046 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively; liquidation preference of $14,000 as of December 31, 2013, owned by Cocrystal Discovery shareholders, converted in the merger with Biozone.    10,108us-gaap_PreferredStockValue
Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, issued and outstanding at December 31, 2014, issued in the merger with RFS Pharma, LLC 178,218cocp_SeriesConvertiblePreferredStock0.001ParValue1000SharesAuthorizedIssuedAndOutstandingAtDecember312014IssuedInMergerWithRfsPharmaLlc   
Shareholders' equity    
Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 1,000 and 279 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively 1cocp_SeriesBConvertiblePreferredStock.001ParValue5000SharesAuthorized1000And279SharesIssuedAndOutstandingAtDecember312014AndDecember312013Respectively   
Common stock, $.001 par value; 200,000 and 262,186 shares authorized, 122,494 and 0 shares issued and outstanding as of December 31, 2014 and December 31, 2013, respectively 123us-gaap_CommonStockValue   
Additional paid-in capital 18,725us-gaap_AdditionalPaidInCapital 3,502us-gaap_AdditionalPaidInCapital
Accumulated other comprehensive income, net of tax 236us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax   
Accumulated deficit (12,434)us-gaap_RetainedEarningsAccumulatedDeficit (12,335)us-gaap_RetainedEarningsAccumulatedDeficit
Total stockholders' equity (deficit) 6,651us-gaap_StockholdersEquity (8,833)us-gaap_StockholdersEquity
Total liabilities and stockholders' equity (deficit) $ 259,283us-gaap_LiabilitiesAndStockholdersEquity $ 1,661us-gaap_LiabilitiesAndStockholdersEquity